Scarica l'app Stockscreener
27.88
1.90%
-0.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.42
Aprire:
$27.95
Volume 24 ore:
487.20K
Relative Volume:
1.51
Capitalizzazione di mercato:
$1.54B
Reddito:
$29.71M
Utile/perdita netta:
$-69.15M
Rapporto P/E:
-54.35
EPS:
-0.513
Flusso di cassa netto:
$-52.28M
1 W Prestazione:
-12.22%
1M Prestazione:
+50.05%
6M Prestazione:
+24.46%
1 anno Prestazione:
+74,846%
Intervallo 1D:
$26.52
$28.64
Intervallo di 1 settimana:
$25.84
$32.38
Portata 52W:
$14.72
$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
Nome
Aktis Oncology Inc
Settore
Industria
Telefono
978-237-4380
Indirizzo
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
27.88 | 1.54B | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-03 | Iniziato | BofA Securities | Buy |
| 2026-02-03 | Iniziato | JP Morgan | Overweight |
| 2026-02-03 | Iniziato | Leerink Partners | Outperform |
| 2026-02-03 | Iniziato | TD Cowen | Buy |
| 2024-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Iniziato | B. Riley Securities | Buy |
| 2021-02-02 | Reiterato | Craig Hallum | Buy |
| 2021-01-15 | Reiterato | Craig Hallum | Buy |
| 2019-09-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Iniziato | Craig Hallum | Buy |
| 2018-11-30 | Iniziato | Lake Street | Buy |
| 2018-06-22 | Iniziato | Loop Capital | Buy |
| 2018-02-09 | Iniziato | Drexel Hamilton | Buy |
Mostra tutto
Aktis Oncology Inc Borsa (AKTS) Ultime notizie
Aktis oncology CMO sells $1.39m in shares By Investing.com - Investing.com Australia
Aktis Oncology COO Ron-Bigger sells $1.39m in shares - Investing.com UK
Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing - Moomoo
Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com - Investing.com Australia
Form 4 Aktis Oncology Inc For: 10 July By Investing.com - Investing.com Nigeria
Aktis Oncology Insiders Sold Shares Worth Over $2.8M - TradingView
Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares - Stock Titan
Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades - Stock Titan
Form 144 AKTIS ONCOLOGY For: 8 July By Investing.com - Investing.com UK
[144] Aktis Oncology, Inc. SEC Filing - Stock Titan
Certain Options of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com
34,872,279 Common Stock of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga
Aktis is a strong buy at Raymond James on therapeutic platform - MSN
Aktis Oncology, Inc. Actuals & Estimates (NASDAQ:AKTS) - TradingView
AKTS Forecast — Price Target — Prediction for 2027 - TradingView
Aktis Oncology, Inc. News — NASDAQ:AKTS - TradingView
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Global BMI Index - marketscreener.com
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage; Stock RisesEarnings Deceleration Risk - dars.gov.et
Aktis Oncology (AKTS) Gains Strong Buy Rating from Raymond James - GuruFocus
Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ) - Seeking Alpha
AKTS Initiates Coverage On by Raymond James -- Rating Set to Str - GuruFocus
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Raymond James initiates Aktis Oncology stock coverage with buy rating By Investing.com - Investing.com Canada
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - AOL.com
Aktis Oncology (AKTS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday - Benzinga
Aktis Oncology: Mini-Proteins With A Targeted Punch (NASDAQ:AKTS) - Seeking Alpha
AKTS: Advancing novel radiopharmaceuticals with strong early data, robust supply, and pipeline growth - TradingView
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $35 - Moomoo
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Amid Development ProgressTangible Book Value - newsline.com
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $35 - Moomoo
AKTS Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
AKTS Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressGrowth Acceleration Report - newsline.com
Aktis Oncology CEO to present new targeted radiopharmaceuticals at Jefferies Healthcare Conference - Pluang
Aktis Oncology to Present at the Jefferies Global Healthcare Conference - The Manila Times
a16z Capital Management, L.L.C.'s Aktis Oncology Inc(AKTS) Holding History - GuruFocus
AKTSAktis Oncology Inc Stock Price and Quote - Finviz
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance
Top Premarket Gainers - Moomoo
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors - The Manila Times
Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative
Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire
Top Cybin (HELP) Competitors 2026 - MarketBeat
Aktis Oncology Inc Azioni (AKTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aktis Oncology Inc Azioni (AKTS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ron-Bigger Shulamit | Chief Operating Officer |
Jul 08 '26 |
Sale |
27.75 |
50,000 |
1,387,558 |
0 |
| Czibere Akos | Chief Medical Officer |
Jul 08 '26 |
Option Exercise |
4.95 |
50,000 |
247,500 |
50,000 |
| Czibere Akos | Chief Medical Officer |
Jul 08 '26 |
Sale |
27.77 |
50,000 |
1,388,701 |
0 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):